News

Thyroid cancer outcomes worse for black and Hispanic young adults


 

FROM THYROID

References

African American and Hispanic adolescents and adults under the age of 40 years were more likely to die from differentiated thyroid cancer than were non-Hispanic whites from the same age range, said the authors of a newly published study in Thyroid.

Lead author Theresa H.M. Keegan, Ph.D., of Stanford (Calif.) University and her associates used the California Cancer Registry to obtain data on 16,827 adolescents and young adults who had a diagnosis of differentiated thyroid cancer between 1988 and 2010. Older young adults aged 35-39 years (versus 15- to 29-year-olds), men (hazard ratio, 2.77; 95% confidence interval, 1.62-4.72), and adolescents and young adults of African American or Hispanic race/ethnicity (versus non-Hispanic whites) had worse thyroid cancer–specific survival than did non-Hispanic whites, judging from findings of multivariate analyses using Cox proportional hazards regression.

In addition, residence in low-socioeconomic-status neighborhoods (HR, 3.11; 95% CI, 1.28-7.56) and nonmetropolitan areas (HR, 5.53; 95% CI, 2.07-14.78) was associated with worse thyroid cancer–specific survival among adolescent and young adult men but not adolescent and young adult women.

“Our study is one of the first to simultaneously consider the impact of small-area neighborhood [socioeconomic status], health insurance, marital status, diagnosis of subsequent cancers, and a number of tumor characteristics on survival after” differentiated thyroid cancer in adolescents and young adults, the authors noted.

Read the full article here (Thyroid 2015;25:635-48 [doi:10.1089/thy.2015.0021]).

The authors reported that they did not have any competing financial interests.

mbock@frontlinemedcom.com

Recommended Reading

Ultrasound bests elastography for specificity of thyroid cancer diagnosis
MDedge Hematology and Oncology
Study aims to determine prognostic factors for subset of thyroid cancer patients
MDedge Hematology and Oncology
Lenvima gets the FDA’s nod for differentiated thyroid cancer
MDedge Hematology and Oncology
Most thyroid nodules have favorable prognosis
MDedge Hematology and Oncology
SEER: Breast cancer survivors at increased risk of thyroid cancer
MDedge Hematology and Oncology
VIDEO: Meet Frankie and Sophie, the thyroid cancer–sniffing dogs
MDedge Hematology and Oncology
VIDEO: Following breast cancer diagnosis, risk of thyroid cancer rises
MDedge Hematology and Oncology
Add baseline DHEAS when screening adrenal incidentalomas for subclinical hypercortisolism
MDedge Hematology and Oncology
AACE: How to safely skip radioactive iodine for low-grade thyroid cancer
MDedge Hematology and Oncology
ASA: Mutation testing aids decision making in thyroid cancer
MDedge Hematology and Oncology